M Pharma Fp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mayne Pharma Group Ltd (MYX)
Track the Mayne Pharma share price today and view real-time MYX share price data, including charts, technicals, and key financials. View the MYX premarket stock price ahead of the market session or assess the after hours quote. Explore MYX stock price movements, trading volume, and market activity across the ASX exchange.
What Is the Mayne Pharma Stock Price Today?
The Mayne Pharma stock price today is 3.010.
What Is the Stock Symbol for Mayne Pharma?
The stock symbol for Mayne Pharma is ""MYX.""
What Stock Exchange Does Mayne Pharma Trade On?
Mayne Pharma is listed and trades on the Sydney stock exchange.
Is Mayne Pharma a Good Stock to Buy?
Determining whether Mayne Pharma or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MYX quote. (ISIN: AU000000MYX0)
What Is the Mayne Pharma Stock Price Today?
The Mayne Pharma stock price today is 3.010.
What Is the Stock Symbol for Mayne Pharma?
The stock symbol for Mayne Pharma is ""MYX.""
What Stock Exchange Does Mayne Pharma Trade On?
Mayne Pharma is listed and trades on the Sydney stock exchange.
Is Mayne Pharma a Good Stock to Buy?
Determining whether Mayne Pharma or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MYX quote. (ISIN: AU000000MYX0)
3.010
-0.110(-3.53%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.900
3.150
52 wk Range
2.040
6.500
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.9003.150
52 wk Range
2.0406.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
MYX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
4.500
Upside
+49.50%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
- M Pharma Fp receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
M Pharma Fp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.500
(+49.50% Upside)
Mayne Pharma Group Ltd Earnings Call Summary for H2/2026
- Mayne Pharma reported FY2026 revenue of AUD 383.7M (down 6%), but gross margin expanded 411 bps to 64.7% on improved product mix and pricing.
- Underlying EBITDA fell 27% to AUD 34.2M due to higher sales/marketing spend, FX headwinds, and litigation costs from Cosette dispute.
- Women's health products BIJUVA, IMVEXXY, and NEXTSTELLIS grew; new distribution platform DistributeRx added 5,000 prescribers, expanding capacity.
- Management expects FY2027 margin improvement from women's health growth, reduced one-off costs, and resolution of ANNOVERA product returns.
- Stock unchanged at $3.17; company remains unprofitable with cash position declining to AUD 80M from AUD 100.4M year-over-year.
Last Updated: 27/08/2026, 10:24 am
Read Full TranscriptEarnings
Latest Release
26/08/2026
EPS / Forecast
-- / --
Revenue / Forecast
86.5M / --
Compare MYX to Peers and Sector
Metrics to compare | MYX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMYXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 7.8x | 11.6x | −0.4x | |
PEG Ratio | 0.07 | 0.01 | 0.00 | |
Price/Book | 0.6x | 2.6x | 2.6x | |
Price / LTM Sales | 0.6x | 3.1x | 3.1x | |
Upside (Analyst Target) | 49.5% | 41.7% | 48.2% | |
Fair Value Upside | Unlock | 18.6% | 6.5% | Unlock |
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women’s Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Mayne Pharma (MYX) Stock Price Today?
The Mayne Pharma stock price today is 3.010 AUD.
What Stock Exchange Does Mayne Pharma Trade On?
Mayne Pharma is listed and trades on the Sydney Stock Exchange.
What Is the Stock Symbol for Mayne Pharma?
The stock symbol for Mayne Pharma is "MYX."
What Is the Mayne Pharma Market Cap?
As of today, Mayne Pharma market cap is 244.550M AUD.
What Is Mayne Pharma's Earnings Per Share (TTM)?
The Mayne Pharma EPS (TTM) is -1.038.
When Is the Next Mayne Pharma Earnings Date?
Mayne Pharma will release its next earnings report on 19/11/2026.
From a Technical Analysis Perspective, Is MYX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Mayne Pharma Stock Split?
Mayne Pharma has split 4 times.
How Many Employees Does Mayne Pharma Have?
Mayne Pharma has 491 employees.
What is the current trading status of Mayne Pharma (MYX)?
As of 29/08/2026, Mayne Pharma (MYX) is trading at a price of 3.010 AUD, with a previous close of 3.120 AUD. The stock has fluctuated within a day range of 2.900 AUD to 3.150 AUD, while its 52-week range spans from 2.040 AUD to 6.500 AUD.
What Is Mayne Pharma (MYX) Price Target According to Analysts?
The average 12-month price target for Mayne Pharma is 4.500 AUD, with a high estimate of 5.25 AUD and a low estimate of 3.75 AUD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +49.50% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.